Articles

Surgery and radiation are considered the standard of care for estrogen receptor–negative (ER–) breast cancer. However, adjuvant chemotherapy may have a role in treating isolated ER– breast cancer recurrences, according to results of the Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer (CALOR) trial presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Read More ›

Young women with triple-negative and luminal-type breast cancer were more likely to respond to neoadjuvant chemotherapy than were older women with these cancers, and improved outcomes were observed for young women with luminal-A–like tumors who achieved a pathologic complete response (pCR) versus those who did not. Read More ›

“Sexual and intimacy issues are the white elephant in the room for women with breast cancer,” stated Susan W. Rafte, of the Pink Ribbons Project, Houston, Texas. Read More ›

Colorectal cancer (CRC) is the third most common type of non– ‒skin cancer in both men and women. Read More ›

I spent 8 long months in a city far from my own, undergoing intense chemotherapy and then an autologous stem cell transplant. Read More ›

A 500-mg dose of fulvestrant improved survival compared with a 250-mg dose in women with estrogen receptor–positive (ER+) metastatic breast cancer with no increase in toxicity, according to an update of the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial. Read More ›

Extending tamoxifen treatment for 10 years reduced the risk of dying by 29% compared with the standard 5 years of tamoxifen for estrogen receptor–positive (ER+) breast cancer, but these benefits of longer-duration tamoxifen did not emerge until the second decade after diagnosis, according to results of the international Adjuvant Tamoxifen—Longer Against Shorter (ATLAS) study. Read More ›

Two years of trastuzumab provide no benefit over the standard of 1 year of trastuzumab therapy for human epidermal growth factor receptor 2–positive (HER2+) breast cancer, according to an 8-year follow-up of the Herceptin Adjuvant (HERA) trial reported by Martine Piccart, MD, president of the European Society for Medical Oncology and chair of the Breast International Group, Institut Jules Bordet, Brussels, Belgium. Read More ›

A 10-year follow-up of the 2-part UK Standardisation of Breast Radiotherapy Trial (START) supports the 5-year findings, which demonstrated that a shorter course of adjuvant radiation therapy is equivalent to a 5-week course of radiation for women with invasive breast cancer. Read More ›

Cognitive changes identified in patients undergoing chemotherapy are common and referred to as “chemo brain.” Read More ›